Bi Asset Management Fondsmaeglerselskab A Belite Bio, Inc Put Options Transaction History
Bi Asset Management Fondsmaeglerselskab A
- $9.48 Billion
- Q4 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding BLTE
# of Institutions
22Shares Held
94KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$9.5 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.13 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.04 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$827,9580.0% of portfolio
-
Ubs Group Ag12.2KShares$690,5490.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.41B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...